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Introduction 
Inflammatory responses following vascular endothelial dysfunction have been 
considered critical and initial steps leading to the pathogenesis of many diseases, 
such as hypertension, ischemia/reperfusion (I/R) injury, and vascular complications 
in diabetes. Endothelial dysfunction is characterized by increase in reactive oxygen 
species (ROS) and decrease in endothelial-derived nitric oxide (NO). Under normal 
physiological conditions, endothelial-derived NO is produced via endothelial NO 
synthase (eNOS) and is a key component  of vascular homeostasis responsible for 
regulating normal blood pressure, vasodilation, anti-inflammatory responses, and 
anti-coagulation properties. It has been shown that decrease in NO bioavailability 
by NG-nitro-L-arginine-methyl-ester (L-NAME), a non-selective NOS inhibitor, 
can induce inflammatory responses (1). On the other hand, vascular endothelial 
NADPH oxidase produces ROS normally at small quantity for the purposes of 
signaling transduction and cellular regulation. However, during pathological 
conditions, NO bioavailability is decreased and leukocyte NADPH oxidase is 
activated via assembly of its subunits on the cell membrane resulting in 
overproduction of superoxide (SO) and subsequent hydrogen peroxide (H2O2) 
release and leading to oxidative stress. Furthermore, SO can directly react with NO 
to produce peroxynitrite (ONOO-) and thereby decreases NO bioavailability, 
exacerbates endothelial dysfunction, and subsequently initiates leukocyte-
endothelial interactions. Therefore, the recruitment of leukocytes will amplify the 
inflammatory responses and lead to tissue and organ damage. However, it is still 
unclear of the role of NADPH oxidase in leukocyte-endothelial under basal level 
and activated status during inflammatory responses. In this study, two NADPH 
oxidase inhibitors, apocynin and Gp91 ds-tat will be tested on basal and L-NAME 
induced leukocyte-endothelial interactions. Apocynin or Gp91 ds-tat, prevent the 
assembly of catalytic subunits of the enzyme and thereby inhibit SO release from 
NADPH oxidase as shown in figure 1 (2-4). 
Methods 
Conclusions 
We hypothesized that L-NAME treatment will induce leukocyte-endothelial 
interactions. Furthermore, apocynin will not influence basal leukocyte-endothelial 
interactions. Moreover, apocynin or Gp91ds-tat will dose-dependently attenuate L-
NAME induced leukocyte-endothelial interactions.  
Results 
Intravital microscopy 
Male Sprague-Dawley rats, weighing 275-325 g, were anesthetized with 60 mg/kg 
pentobarbital sodium intraperitoneally (i.p.) and maintained with 30 mg/kg 
pentobarbital sodium (i.p.). The left carotid was isolated and cannulated to monitor 
the mean arterial blood pressure (MABP). A loop of the ileal mesentery was 
exteriorized via midline laparotomy and superfused with physiological buffer (i.e. 
Krebs’ buffer) or Krebs’ buffer with different treatments (Table 1). After 30 min 
stabilization, Leukocyte-endothelial interactions within the mesenteric postcapillary 
venules were observed via intravital microscopy for 2 hr. After the experiment, 
mesenteric tissue was harvested for hematoxylin and eosin (H&E) staining to 
evaluate leukocyte adherence and transmigration. All data is represented as means 
± standard error of the mean (SEM). The comparison of more than two groups was 
analyzed by ANOVA using post hoc analysis with the Bonferroni/Dunn test to 
detect differences among experimental groups with each aim. Probability values of 






L-NAME treatment significantly increased leukocyte-endothelial interactions 
compared to the Krebs’ buffer control (p<0.01). Apocynin had less influence on 
basal leukocyte-endothelial interactions. However, apocynin or Gp91 ds-tat dose-
dependently attenuated L-NAME induced leukocyte-endothelial interactions  with 
time (p<0.01). High dose of apocynin (1000 µM) suggested that apocynin exerted 
inflammatory responses independent of inhibition of NADPH oxidase. The results 
suggested that inhibiting the assembly of NAPDH oxidase is an important 
mechanism to attenuate leukocyte-endothelial interactions induced by endothelial 
dysfunction. Therefore, NADPH oxidase inhibitors may be beneficial to mitigate 
the pathogenesis of inflammatory-mediated vascular diseases. 
Figure 1. Apocynin and Gp91 ds-tat inhibit the assembly of catalytic subunits of 
NADPH oxidase. Apocynin inhibits the translocation of p47phox along with other 
cytosolic subunits (p67phox and p40phox) to the membranous subunits (gp91phox 
and p22phox). Gp91 ds-tat contains gp91phox docking sequence, which binds to 
p47phox and prevents the interaction of p47phox with gp91phox and thereby 
inhibits the assembly of NADPH oxidase. Adapted and modified from Brandes RP 
2003 (2). 
Table 1. Experimental Groups 
1.       Control (n=6) superfusion of Krebs’ buffer  
2-3.      Apocynin (n=5-7) superfusion of 400 µM/ 1000 µM in Krebs’ buffer 
4.       L-NAME (n=5) superfusion of 50 µM L-NAME 
5-7. L-NAME+Apocynin 
(n=6-7) 
superfusion of 50 µM L-NAME with 40 µM/ 400 
µM/ 1000 µM apocynin  
8-9 L-NAME+Gp91 ds-tat 
(n=4-6) 
superfusion of 50 µM L-NAME with 5 µM/ 20 µM 
Gp91 ds-tat  
Figure 2. Experimental setup for intravital microscopy. Inserted picture upper right: 
exteriorized loop of mesenteric tissue undergoing superfusion of test solution. 
Figure 3. Leukocyte rolling among different experimental groups. 50 µM L-NAME 
significantly increased leukocyte rolling  at T=90 min and T=120 min (**P<0.01 
from Krebs’). The effect of L-NAME was significantly attenuated  by the 
administration of 40 μM or 400 µM apocynin at T=60, 90, &120 min (left panel) 
and 20 µM Gp91 ds-tat at T=90 & 120min (right panel) (##P<0.01 from L-NAME).  
 
Figure 4. Leukocyte adherence among different experimental groups. 50 µM L-
NAME significantly increased leukocyte adherence at T=60, 90, and 120 min 
(**P<0.01 from Krebs’). The effect of L-NAME was significantly attenuated  by 
the administration of 40 μM or 400 µM apocynin at T=60, 90, &120 min (left 
panel) and 20 µM Gp91 ds-tat at T=90 & 120 min (right panel) (##P<0.01 from 
L-NAME).  
Figure 5. Leukocyte transmigration among different experimental groups. 50 µM 
L-NAME significantly increased leukocyte transmigration at T=60, 90, and 120 
min (**P<0.01 from Krebs’). The effect of L-NAME was significantly attenuated  
by the administration of 40 μM or 400 µM apocynin at T=60, 90, &120 min (left 
panel) and 20 µM Gp91 ds-tat at T=90 & 120 min (right panel) (##P<0.01 from 
L-NAME).  
Figure 6. Representative pictures (20x) of leukocytes by H&E staining of 
mesenteric tissue from Krebs’ control (A), L-NAME (B), L-NAME+ 400 µM 
apocynin (C), L-NAME+ 20 µM Gp91 ds-tat (D). L-NAME treatment exhibited a 
marked increase in leukocyte vascular adherence and transmigration compared to 
Krebs’ buffer. By contrast, apocynin or Gp91 ds-tat exhibited a marked decrease 
in adherent and transmigrated leukocytes compared to L-NAME. Black arrow 
indicates adherence and red arrow indicate transmigration (scale bar: 20 μm).  
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